The effect of anti-TNF therapy on thyroid function in patients with inflammatory bowel disease

Autor: Androniki Poulou, Andromachi Vryonidou, Grigoris Effraimidis, Vasiliki Loi, Fotios Kothonas, Eleni Palioura, Konstantinos Goumas, Alexandros Myroforidis, Stavroula A Paschou
Rok vydání: 2018
Předmět:
Adult
Male
endocrine system
medicine.medical_specialty
endocrine system diseases
Endocrinology
Diabetes and Metabolism
medicine.medical_treatment
Thyroid Gland
Thyrotropin
030209 endocrinology & metabolism
Thyroid Function Tests
Inflammatory bowel disease
Gastroenterology
03 medical and health sciences
0302 clinical medicine
Endocrinology
Gastrointestinal Agents
Thyroid-stimulating hormone
Thyroid peroxidase
Internal medicine
Azathioprine
Humans
Medicine
Mesalamine
Triiodothyronine
biology
business.industry
Anti-Inflammatory Agents
Non-Steroidal
Thyroid
Adalimumab
Middle Aged
Inflammatory Bowel Diseases
medicine.disease
Infliximab
Thyroid disorder
Thyroxine
medicine.anatomical_structure
030220 oncology & carcinogenesis
biology.protein
Female
Thyroglobulin
Thyroid function
business
hormones
hormone substitutes
and hormone antagonists
Zdroj: Endocrine Journal. 65:1121-1125
ISSN: 1348-4540
0918-8959
DOI: 10.1507/endocrj.ej18-0243
Popis: The aim of this study was to investigate for first time the thyroid function in patients with inflammatory bowel disease (IBD) and the potential effect of anti-TNF (tumor necrosis factor) therapy. We evaluated 41 patients with IBD (25M/16F, 36.5 ± 11.3 y, 27 with Crohn's disease and 14 with ulcerative colitis), without any known thyroid disorder. Eighteen patients (9M/9F, 33.6 ± 8.8 y) were on anti-TNF therapy, while 23 patients (16M/7F, 38.7 ± 12.5 y) were treated with Azathioprine and Mesalazine (Aza/Mes) for more than 1 year. Twelve patients from the second group were then treated with anti-TNF and studied 6 months later. We assessed thyroid function by measuring thyroid stimulating hormone (TSH), free thyroxine (FT4), triiodothyronine (T3), thyroid peroxidase autoantibodies (TPOAb) and thyroglobulin autoantibodies (TgAb) levels. One patient presented with overt and one with subclinical hyperthyroidism. Thyroid auto-antibodies were positive in 12.2%. Patients from the anti-TNF group had lower levels of FT4 (1.09 ± 0.15 vs. 1.38 ± 0.9 ng/dL, p = 0.042), while TSH and T3 were comparable. The percentage of patients with positive thyroid auto-antibodies was lower in the anti-TNF group (5.6% vs. 17.4%). In the subgroup of patients who changed to anti-TNF, we found statistically significant reduction in FT4 after 6 months (1.26 ± 0.24 vs. 1.08 ± 0.15 ng/dL, p = 0.044), without changes in TSH and T3 levels. There was no change regarding thyroid auto-antibodies. In conclusion, patients with IBD showed a quite high percentage of thyroid autoimmunity. After treatment with anti-TNF, FT4 levels were found to be reduced, while no changes in TSH, T3 levels and thyroid auto-antibodies were noted.
Databáze: OpenAIRE
Externí odkaz: